Bibliographic Details
| Title: |
Efficacy of halopeRIdol to decrease the burden of Delirium In adult Critically ill patiEnts (EuRIDICE): study protocol for a prospective randomised multi-centre double-blind placebo-controlled clinical trial in the Netherlands |
| Authors: |
John W Devlin, Zoran Trogrlic, Mathieu van der Jagt, Lisa Smit, Robert-Jan Osse, Huibert H Ponssen, Arjen J C Slooter, Nicole G M Hunfeld, Wim J R Rietdijk, Diederik Gommers, M. van den Boogaard, A.J.B.W. Brouwers, J.A. Lens, B.J.M. van der Meer, H. Ponssen, F.J. Schoonderbeek, K.S. Simons, E. Berger, A. Bouman, M. Campo, D. van Duijn, H. Embden – van Donk, D. van de Graaf, E. Hoogendoorn, P. Ormskerk, N. Roovers, E. Toscano, A. Vileito, T. van Zuylen, C. Exler, E. van den Berg, J. van Meeteren, M. Koopmanschap, I. Nutma, E. Kuijper |
| Source: |
BMJ Open, Vol 10, Iss 9 (2020) |
| Publisher Information: |
BMJ Publishing Group, 2020. |
| Publication Year: |
2020 |
| Collection: |
LCC:Medicine |
| Subject Terms: |
Medicine |
| More Details: |
Introduction Delirium in critically ill adults is associated with prolonged hospital stay, increased mortality and greater cognitive and functional decline. Current practice guideline recommendations advocate the use of non-pharmacological strategies to reduce delirium. The routine use of scheduled haloperidol to treat delirium is not recommended given a lack of evidence regarding its ability to resolve delirium nor improve relevant short-term and longer-term outcomes. This study aims to evaluate the efficacy and safety of haloperidol for the treatment of delirium in adult critically ill patients to reduce days spent with coma or delirium.Methods and analysis EuRIDICE is a prospective, multi-centre, randomised, double-blind, placebo-controlled trial. Study population consists of adult intensive care unit (ICU) patients without acute neurological injury who have delirium based on a positive Intensive Care Delirium Screening Checklist (ICDSC) or Confusion Assessment Method for the ICU (CAM-ICU) assessment. Intervention is intravenous haloperidol 2.5 mg (or matching placebo) every 8 hours, titrated daily based on ICDSC or CAM-ICU positivity to a maximum of 5 mg every 8 hours, until delirium resolution or ICU discharge. Main study endpoint is delirium and coma-free days (DCFD) up to 14 days after randomisation. Secondary endpoints include (1) 28-day and 1-year mortality, (2) cognitive and functional performance at 3 and 12 months, (3) patient and family delirium and ICU experience, (4) psychological sequelae during and after ICU stay, (4) safety concerns associated with haloperidol use and (5) cost-effectiveness. Differences in DCFDs between haloperidol and placebo group will be analysed using Poisson regression analysis. Study recruitment started in February 2018 and continues.Ethics and dissemination The study has been approved by the Medical Ethics Committee of the Erasmus University Medical Centre Rotterdam (MEC2017-511) and by the Institutional Review Boards of the participating sites. Its results will be disseminated via peer-reviewed publication and conference presentations.Trial registration NCT03628391 |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2044-6055 |
| Relation: |
https://bmjopen.bmj.com/content/10/9/e036735.full; https://doaj.org/toc/2044-6055 |
| DOI: |
10.1136/bmjopen-2019-036735 |
| Access URL: |
https://doaj.org/article/d5b1d0870108471abc96d800db9b2f17 |
| Accession Number: |
edsdoj.5b1d0870108471abc96d800db9b2f17 |
| Database: |
Directory of Open Access Journals |
